Diabetic Foot Ulcers Treatment Market is estimated to be valued at USD 10.36 Bn in 2026 and is expected to reach USD 20.70 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.4% from 2026 to 2033.
| Report Coverage |
Report Details |
| Base Year: |
2025 |
Market Size in 2026: |
USD 10.36 Bn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: |
10.40% |
2033 Value Projection: |
USD 20.70 Bn |
Diabetic foot ulcer is a common condition in diabetic patients, which may lead to amputation of the leg. People who rely on insulin for the treatment of diabetes are at high risk of developing a foot ulcer. Moreover, people suffering from diabetes-related kidney, eye, and heart disease and obesity can also suffer from diabetic foot ulcers. The risk of the disease is high in those consuming alcohol and tobacco. The common initial symptoms of diabetic foot ulcer include unusual swelling, redness, irritation, and stenches on one or both feet. Diabetic foot ulcer treatment, usually include control of blood sugar, removal of dead tissue, wound dressings, and negative pressure therapy.
Market Dynamics
Key players operating in the global diabetic foot ulcer treatment market are focusing on adoption of growth strategies such as product launches and regulatory approvals, which are expected to drive the market growth during the forecast period. For instance, in November 2019, Pergamum AB, a subsidiary of Promore Pharma AB, a Sweden-based biopharmaceutical company, received a patent in the U.S. for the pharmaceutical formulation of the product candidate PXL01 used for the treatment of diabetic foot ulcers. Moreover, in December 2019, Orpyx Medical Technologies Inc., a medical device company that designs and develops sensory insole systems for the treatment of diabetic foot ulcers, launched Orpyx SI Sensory Insoles with for the prevention of diabetic foot ulcers and neuropathy-related ulcers. Furthermore, in December 2017, SANUWAVE Health Inc., received the US approval for marketing of the Dermapace system, the indicated to treat diabetic foot ulcer.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for global diabetic foot ulcer treatment market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global diabetic foot ulcer treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include 3M Healthcare, B. Braun Melsungen AG, Smith & Nephew, Inc., Organogenesis, Inc., Derma Sciences Inc., Sigvaris Inc., Acelity L.P. Inc., Osiris, and Molnlycke Health Care AB
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global diabetic foot ulcer treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diabetic foot ulcer treatment market
Detailed Segmentation:
- Global Diabetic Foot Ulcer Treatment Market, By Product (Revenue, USD Bn, 2021 - 2033)
- Advance Wound Dressings
- Skin Substitutes
- Growth Factors
- Negative Pressure Wound Therapy Devices
- Other Devices
- Global Diabetic Foot Ulcer Treatment Market, By Ulcer Type (Revenue, USD Bn, 2021 - 2033)
- Neuropathic Ulcers
- Ischemic Ulcers
- Neuro-ischemic Ulcers
- Global Diabetic Foot Ulcer Treatment Market, By End User (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty Clinics
- Long Term Care Centers
- Ambulatory Surgical Center
- Global Diabetic Foot Ulcer Treatment Market, By Region (Revenue, USD Bn, 2021 - 2033)
- North America
- By Product
- Advance Wound Dressings
- Skin Substitutes
- Growth Factors
- Negative Pressure Wound Therapy Devices
- Other Devices
- By Ulcer Type
- Neuropathic Ulcers
- Ischemic Ulcers
- Neuro-ischemic Ulcers
- By End User
- Hospitals
- Specialty Clinics
- Long Term Care Centers
- Ambulatory Surgical Center
- By Country
- Latin America
- By Product
- Advance Wound Dressings
- Skin Substitutes
- Growth Factors
- Negative Pressure Wound Therapy Devices
- Other Devices
- By Ulcer Type
- Neuropathic Ulcers
- Ischemic Ulcers
- Neuro-ischemic Ulcers
- By End User
- Hospitals
- Specialty Clinics
- Long Term Care Centers
- Ambulatory Surgical Center
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Product
- Advance Wound Dressings
- Skin Substitutes
- Growth Factors
- Negative Pressure Wound Therapy Devices
- Other Devices
- By Ulcer Type
- Neuropathic Ulcers
- Ischemic Ulcers
- Neuro-ischemic Ulcers
- By End User
- Hospitals
- Specialty Clinics
- Long Term Care Centers
- Ambulatory Surgical Center
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Product
- Advance Wound Dressings
- Skin Substitutes
- Growth Factors
- Negative Pressure Wound Therapy Devices
- Other Devices
- By Ulcer Type
- Neuropathic Ulcers
- Ischemic Ulcers
- Neuro-ischemic Ulcers
- By End User
- Hospitals
- Specialty Clinics
- Long Term Care Centers
- Ambulatory Surgical Center
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Product
- Advance Wound Dressings
- Skin Substitutes
- Growth Factors
- Negative Pressure Wound Therapy Devices
- Other Devices
- By Ulcer Type
- Neuropathic Ulcers
- Ischemic Ulcers
- Neuro-ischemic Ulcers
- By End User
- Hospitals
- Specialty Clinics
- Long Term Care Centers
- Ambulatory Surgical Center
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Product
- Advance Wound Dressings
- Skin Substitutes
- Growth Factors
- Negative Pressure Wound Therapy Devices
- Other Devices
- By Ulcer Type
- Neuropathic Ulcers
- Ischemic Ulcers
- Neuro-ischemic Ulcers
- By End User
- Hospitals
- Specialty Clinics
- Long Term Care Centers
- Ambulatory Surgical Center
- By Region/Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
- 3M Healthcare*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Braun Melsungen AG
- Smith & Nephew, Inc.
- Organogenesis, Inc.
- Derma Sciences Inc.
- Sigvaris Inc.
- Acelity L.P. Inc.
- Osiris
- Molnlycke Health Care AB
"*" marked represents similar segmentation in other categories in the respective section.